|
US4197307A
(en)
|
1977-04-12 |
1980-04-08 |
Ciba-Geigy Corporation |
2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents
|
|
EP0377903A3
(de)
|
1989-01-09 |
1991-07-17 |
Bayer Ag |
Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
|
|
DE60020786T2
(de)
|
1999-09-30 |
2006-03-23 |
Pfizer Products Inc., Groton |
6-Azauracilderivate als Liganden der Thyroidrezeptoren
|
|
US6787652B1
(en)
|
1999-09-30 |
2004-09-07 |
Pfizer, Inc. |
6-Azauracil derivatives as thyroid receptor ligands
|
|
GB0015205D0
(en)
*
|
2000-06-21 |
2000-08-09 |
Karobio Ab |
Bioisosteric thyroid receptor ligands and method
|
|
WO2002051805A1
(de)
|
2000-12-27 |
2002-07-04 |
Bayer Aktiengesellschaft |
Indol-derivate
|
|
CA2473162A1
(en)
|
2002-01-30 |
2003-08-07 |
Kissei Pharmaceutical Co., Ltd. |
Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
|
|
WO2003094845A2
(en)
|
2002-05-08 |
2003-11-20 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
|
GB0327319D0
(en)
|
2003-11-24 |
2003-12-24 |
Pfizer Ltd |
Novel pharmaceuticals
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
FR2882750B1
(fr)
|
2005-03-03 |
2007-05-11 |
Pierre Fabre Medicament Sa |
Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
|
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
ATE480524T1
(de)
|
2005-07-21 |
2010-09-15 |
Hoffmann La Roche |
Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
|
|
GB0608724D0
(en)
|
2006-05-03 |
2006-06-14 |
Karobio Ab |
Novel Pharmaceutical Compositions
|
|
WO2007132475A1
(en)
|
2006-05-15 |
2007-11-22 |
Cadila Healthcare Limited |
Selective tr-beta 1 agonist
|
|
GB0610322D0
(en)
*
|
2006-05-24 |
2006-07-05 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
WO2008130637A1
(en)
|
2007-04-18 |
2008-10-30 |
New York University |
Hydrazide compounds as thyroid hormone receptor modulators and uses thereof
|
|
SI2170403T1
(sl)
|
2007-06-27 |
2014-07-31 |
Quark Pharmaceuticals, Inc. |
Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
|
|
TW200906823A
(en)
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
|
US8076334B2
(en)
|
2007-09-20 |
2011-12-13 |
Hoffmann-La Roche Inc. |
Prodrugs of thyroid hormone analogs
|
|
FR2933979B1
(fr)
|
2008-07-15 |
2012-08-24 |
Pf Medicament |
Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
|
|
KR101396606B1
(ko)
|
2009-04-20 |
2014-05-16 |
미쓰비시 타나베 파마 코퍼레이션 |
신규 갑상선 호르몬 β 수용체 작동약
|
|
WO2011038207A1
(en)
|
2009-09-25 |
2011-03-31 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing thyroid hormone receptor agonists and methods of use
|
|
EA023521B1
(ru)
|
2011-11-14 |
2016-06-30 |
Сефалон, Инк. |
ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
|
|
CN103130723B
(zh)
|
2011-11-30 |
2015-01-14 |
成都地奥制药集团有限公司 |
一种多聚(adp-核糖)聚合酶抑制剂
|
|
CN102898377B
(zh)
|
2012-02-14 |
2016-01-20 |
南京圣和药业股份有限公司 |
一类酞嗪酮衍生物及其用途
|
|
ES2795450T3
(es)
|
2012-09-17 |
2020-11-23 |
Madrigal Pharmaceuticals Inc |
Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
|
|
CA2944139C
(en)
|
2014-04-11 |
2020-11-03 |
Cymabay Therapeutics, Inc. |
Treatment of nafld and nash
|
|
CN107074823B
(zh)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
治疗性化合物及其用途
|
|
CN105477636B
(zh)
|
2015-10-16 |
2019-09-17 |
厦门大学 |
使用阿维菌素及其衍生物治疗代谢疾病的方法
|
|
TWI757266B
(zh)
|
2016-01-29 |
2022-03-11 |
美商維它藥物有限責任公司 |
ROR-γ調節劑
|
|
MX2018011813A
(es)
|
2016-03-28 |
2019-01-24 |
Intercept Pharmaceuticals Inc |
Medicina obtenida mediante la combinacion de agonista fxr y arb.
|
|
PL3435996T3
(pl)
|
2016-03-31 |
2025-07-28 |
Genfit |
Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych
|
|
MX2018014024A
(es)
|
2016-05-25 |
2019-08-29 |
Akarna Therapeutics Ltd |
Terapias de combinación con moduladores del receptor x farnesoide (fxr).
|
|
WO2018027892A1
(en)
|
2016-08-12 |
2018-02-15 |
Eli Lilly And Company |
Amino pyrimidine ssao inhibitors
|
|
MX394463B
(es)
|
2016-10-18 |
2025-03-19 |
Madrigal Pharmaceuticals Inc |
Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
|
|
CA3041169A1
(en)
|
2016-10-19 |
2018-04-26 |
Boehringer Ingelheim International Gmbh |
Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
|
|
WO2018103624A1
(zh)
|
2016-12-06 |
2018-06-14 |
江苏恒瑞医药股份有限公司 |
一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
|
|
JP7618384B2
(ja)
|
2017-02-21 |
2025-01-21 |
ジェンフィ |
Pparアゴニストとfxrアゴニストとの組合せ
|
|
SG11201907673YA
(en)
|
2017-03-13 |
2019-09-27 |
Genfit |
Pharmaceutical compositions for combination therapy
|
|
WO2018170173A1
(en)
|
2017-03-15 |
2018-09-20 |
Metacrine, Inc. |
Farnesoid x receptor agonists and uses thereof
|
|
CA3058542A1
(en)
|
2017-04-18 |
2018-10-25 |
Genfit |
Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
|
|
WO2018208707A1
(en)
|
2017-05-08 |
2018-11-15 |
Neurovia, Inc. |
Methods and compositions for treating demyelinating diseases
|
|
US20210121493A1
(en)
|
2017-07-25 |
2021-04-29 |
Cedars-Sinai Medical Center |
Methods for treating liver diseases
|
|
SG11202000748TA
(en)
|
2017-08-25 |
2020-03-30 |
Genfit |
Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
|
|
WO2019053235A1
(en)
|
2017-09-15 |
2019-03-21 |
Genfit |
NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
|
|
EP3684954B1
(en)
|
2017-09-18 |
2025-11-26 |
Genfit |
Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
|
|
US11168079B2
(en)
|
2017-11-01 |
2021-11-09 |
Bristol-Myers Squibb Company |
Alkene compounds as farnesoid x receptor modulators
|
|
US20200340060A1
(en)
|
2017-11-13 |
2020-10-29 |
Gilead Sciences, Inc. |
Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
|
|
CN109574995B
(zh)
*
|
2018-01-23 |
2020-07-24 |
深圳市塔吉瑞生物医药有限公司 |
取代的哒嗪酮化合物
|
|
KR20210002573A
(ko)
|
2018-04-24 |
2021-01-08 |
주식회사 피에이치파마 |
간 질환에 호중구 엘라스타제 저해제의 사용
|
|
ES3029158T3
(en)
|
2018-06-12 |
2025-06-23 |
Xizang Haisco Pharmaceutical Co Ltd |
Thyroid hormone receptor agonists and uses thereof
|
|
WO2020041741A1
(en)
|
2018-08-24 |
2020-02-27 |
Terns, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
EP3844156A4
(en)
|
2018-08-30 |
2022-06-08 |
Terns Pharmaceuticals, Inc. |
TREATMENT OF LIVER DISEASES
|
|
NZ773110A
(en)
|
2018-09-18 |
2024-11-29 |
Terns Inc |
Compounds for treating certain leukemias
|
|
US20220047553A1
(en)
|
2018-09-18 |
2022-02-17 |
Metacrine, Inc. |
Farnesoid x receptor agonists for the treatment of disease
|
|
TWI884745B
(zh)
|
2018-10-12 |
2025-05-21 |
美商拓臻股份有限公司 |
甲狀腺素受體β促效劑化合物
|
|
CN119552152A
(zh)
|
2018-10-12 |
2025-03-04 |
益方生物科技(上海)股份有限公司 |
甲状腺激素受体激动剂
|
|
CN121081472A
(zh)
|
2018-12-13 |
2025-12-09 |
拓臻股份有限公司 |
一种THRβ受体激动剂化合物及其制备方法和用途
|
|
WO2020131578A2
(en)
|
2018-12-17 |
2020-06-25 |
Mitopower Llc |
Nicotinyl riboside compounds and their uses
|
|
CN111484481A
(zh)
|
2019-01-26 |
2020-08-04 |
察略盛医药科技(上海)有限公司 |
哒嗪酮类衍生物、其制备方法及其在医药上的用途
|
|
CN119431265A
(zh)
*
|
2019-02-21 |
2025-02-14 |
南京瑞捷医药科技有限公司 |
一种作为甲状腺激素受体激动剂的化合物
|
|
WO2020227549A1
(en)
|
2019-05-08 |
2020-11-12 |
Aligos Therapeutics, Inc. |
MODULATORS OF THR-β AND METHODS OF USE THEREOF
|
|
WO2020228577A1
(zh)
|
2019-05-10 |
2020-11-19 |
深圳微芯生物科技股份有限公司 |
一种哒嗪酮衍生物及其应用
|
|
WO2020239076A1
(zh)
|
2019-05-29 |
2020-12-03 |
南京明德新药研发有限公司 |
作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
|
|
TW202114672A
(zh)
|
2019-07-23 |
2021-04-16 |
瑞士商諾華公司 |
使用fxr促效劑的肝臟疾病之組合治療
|
|
CN112409340B
(zh)
|
2019-08-21 |
2022-03-18 |
海创药业股份有限公司 |
卤素取代的苯醚类化合物及其用途
|
|
CA3154488A1
(en)
|
2019-08-23 |
2021-03-04 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
CA3154391A1
(en)
|
2019-09-12 |
2021-03-18 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
WO2021121210A1
(zh)
|
2019-12-16 |
2021-06-24 |
江苏恒瑞医药股份有限公司 |
并环类衍生物、其制备方法及其在医药上的应用
|
|
WO2021231646A1
(en)
|
2020-05-13 |
2021-11-18 |
Terns Pharmaceuticals, Inc. |
Combination treatment of liver disorders
|
|
WO2021231644A1
(en)
|
2020-05-13 |
2021-11-18 |
Terns Pharmaceuticals, Inc. |
Combination treatment of liver disorders
|
|
US20220135540A1
(en)
|
2020-10-15 |
2022-05-05 |
Eli Lilly And Company |
Polymorphs of an fxr agonist
|
|
CN114437034A
(zh)
|
2020-11-06 |
2022-05-06 |
深圳微芯生物科技股份有限公司 |
一种酞嗪类化合物的可药用盐、晶型及其制备方法
|
|
MX2023008365A
(es)
|
2021-01-14 |
2023-10-04 |
Enyo Pharma |
Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
|
|
JP2024510935A
(ja)
|
2021-03-03 |
2024-03-12 |
ターンズ・ファーマシューティカルズ・インコーポレイテッド |
甲状腺ホルモン受容体ベータアゴニスト化合物
|
|
US20240239761A1
(en)
|
2021-03-19 |
2024-07-18 |
Medshine Discovery Inc. |
Bicyclic phenol compounds and use thereof
|
|
MX2024005647A
(es)
|
2021-11-11 |
2024-05-24 |
Terns Pharmaceuticals Inc |
Tratamiento de trastornos hepaticos con un agonista del thr-\03b2.
|
|
AU2022387121A1
(en)
|
2021-11-11 |
2024-06-20 |
Terns Pharmaceuticals, Inc. |
Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
|
|
US20230181583A1
(en)
|
2021-11-11 |
2023-06-15 |
Terns Pharmaceuticals, Inc. |
Treating liver disorders with an ssao inhibitor
|
|
WO2023220404A1
(en)
|
2022-05-13 |
2023-11-16 |
Terns Pharmaceuticals, Inc. |
Treatment of non-alcoholic steatohepatitis
|
|
PE20252787A1
(es)
|
2023-04-07 |
2025-12-22 |
Terns Pharmaceuticals Inc |
Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
|